Harbin Pharmaceutical Group Co Ltd (600664) — Cash Flow-to-Debt Ratio
Harbin Pharmaceutical Group Co Ltd (600664) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of CN¥-192.19 Million could theoretically repay 0% of its total liabilities (CN¥7.67 Billion) in one year. See Harbin Pharmaceutical Group Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Harbin Pharmaceutical Group Co Ltd Cash Flow-to-Debt Ratio (1998–2024)
Historical debt coverage capacity for Harbin Pharmaceutical Group Co Ltd across 27 annual periods. Also explore Harbin Pharmaceutical Group Co Ltd annual equity growth to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Harbin Pharmaceutical Group Co Ltd (1998–2024)
Year-by-year debt coverage analysis for Harbin Pharmaceutical Group Co Ltd. For market capitalisation and broader financial context, see 600664 company net worth.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.09x | CN¥792.50 Million | CN¥8.53 Billion | ▼ -15.0% |
| 2023 | 0.11x | CN¥949.67 Million | CN¥8.69 Billion | ▲ +49.1% |
| 2022 | 0.07x | CN¥622.09 Million | CN¥8.48 Billion | ▲ +480.1% |
| 2021 | -0.02x | CN¥-162.44 Million | CN¥8.42 Billion | ▲ +79.2% |
| 2020 | -0.09x | CN¥-728.15 Million | CN¥7.86 Billion | ▼ -113.3% |
| 2019 | -0.04x | CN¥-284.94 Million | CN¥6.56 Billion | ▼ -135.2% |
| 2018 | 0.12x | CN¥692.72 Million | CN¥5.62 Billion | ▲ +413.6% |
| 2017 | 0.02x | CN¥149.22 Million | CN¥6.22 Billion | ▼ -94.2% |
| 2016 | 0.41x | CN¥2.78 Billion | CN¥6.75 Billion | ▲ +55.7% |
| 2015 | 0.26x | CN¥1.66 Billion | CN¥6.28 Billion | ▲ +73.8% |
| 2014 | 0.15x | CN¥1.14 Billion | CN¥7.47 Billion | ▲ +724.6% |
| 2013 | 0.02x | CN¥141.64 Million | CN¥7.68 Billion | ▼ -76.8% |
| 2012 | 0.08x | CN¥557.83 Million | CN¥7.02 Billion | ▲ +1421.6% |
| 2011 | -0.01x | CN¥-31.56 Million | CN¥5.25 Billion | ▼ -102.7% |
| 2010 | 0.22x | CN¥1.15 Billion | CN¥5.22 Billion | ▼ -52.0% |
| 2009 | 0.46x | CN¥1.85 Billion | CN¥4.02 Billion | ▲ +209.8% |
| 2008 | 0.15x | CN¥578.59 Million | CN¥3.89 Billion | ▲ +0.4% |
| 2007 | 0.15x | CN¥650.16 Million | CN¥4.40 Billion | ▼ -11.2% |
| 2006 | 0.17x | CN¥738.08 Million | CN¥4.43 Billion | ▼ -6.8% |
| 2005 | 0.18x | CN¥757.76 Million | CN¥4.24 Billion | ▲ +330.4% |
| 2004 | 0.04x | CN¥149.01 Million | CN¥3.59 Billion | ▼ -52.7% |
| 2003 | 0.09x | CN¥302.83 Million | CN¥3.45 Billion | ▼ -29.6% |
| 2002 | 0.12x | CN¥383.44 Million | CN¥3.08 Billion | ▼ -36.3% |
| 2001 | 0.20x | CN¥604.13 Million | CN¥3.09 Billion | ▲ +2.0% |
| 2000 | 0.19x | CN¥541.70 Million | CN¥2.82 Billion | ▲ +30.7% |
| 1999 | 0.15x | CN¥431.22 Million | CN¥2.94 Billion | ▲ +55.3% |
| 1998 | 0.09x | CN¥221.41 Million | CN¥2.34 Billion | — |